FILING ANALYSIS · MONDAY, OCTOBER 26
Citius Pharmaceuticals, Inc. CTXR — 8-K: Results of Operations and Financial Condition
positive
Citius Pharmaceuticals' subsidiary Citius Oncology reported a 120% increase in LYMPHIR unit sales to U.S. wholesalers in the fiscal fourth quarter, with 792 units sold, and 950 vials ordered by prescribing centers, indicating strong demand and growth momentum for the product.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →